Related Experiment Videos
Variable oral absorption of hexamethylmelamine in man
Cancer Treatment Reports
|December 1, 1978
Summary
This study measured plasma levels of hexamethylmelamine (HMM) in patients. HMM did not accumulate in plasma during daily treatment, indicating predictable pharmacokinetics.
Area of Science:
- Pharmacology
- Clinical Chemistry
- Oncology
Background:
- Hexamethylmelamine (HMM) is an antineoplastic agent.
- Understanding HMM pharmacokinetics is crucial for optimizing cancer therapy.
- Previous studies have indicated variable drug levels, necessitating further investigation.
Purpose of the Study:
- To quantify plasma hexamethylmelamine levels in cancer patients.
- To characterize the pharmacokinetic profile of orally administered HMM.
- To assess potential drug accumulation during prolonged treatment.
Main Methods:
- Gas chromatographic assay used for sensitive and specific HMM quantification.
- 11 patients received oral HMM doses (120–300 mg/m²).
- Plasma samples analyzed to determine peak levels, AUC, and elimination half-life.
Main Results:
- Peak HMM plasma concentrations ranged from 0.2 to 20.8 µg/mL, achieved within 0.5–3 hours.
- Area under the curve (AUC) varied from 70.2 to 3606.6 µg/mL × min.
- Elimination half-life showed significant variability (4.66–10.2 hours), independent of dose.
Conclusions:
- Hexamethylmelamine exhibits considerable inter-patient pharmacokinetic variability.
- No significant plasma accumulation of HMM was observed with daily dosing for 14–21 days.
- The findings support consistent dosing strategies for HMM in cancer treatment.